|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Investment securities - available-for-sale (amortized cost $450,934, net of allowance for credit losses of $0 at June 30, 2026 and $472,097, net of allowance for credit losses of $0 at December 31, 2025) | ||||||||||||||||||||
| Restricted investment in bank stocks | ||||||||||||||||||||
| Loans held-for-sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Long-lived assts held for sale | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Noninterest bearing | ||||||||||||||||||||
| Interest bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| FHLB advances, short term | ||||||||||||||||||||
| BTFP borrowings, short term | ||||||||||||||||||||
| FHLB advances, long term | ||||||||||||||||||||
| Subordinated notes, net of issuance costs | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, $0.25 par value; 30,000,000 shares authorized; 13,415,921 and 13,376,464 issued; 13,407,904 and 13,368,447 outstanding, at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Surplus | ||||||||||||||||||||
| Retained Earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net of taxes | ||||||||||||||||||||
| Treasury stock, at cost; 8,017 shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| TOTAL STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
